New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Tillkännagivande • Feb 11
NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026 NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea Tillkännagivande • Feb 12
NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025 NatureCell Co.,Ltd., Annual General Meeting, Mar 31, 2025, at 11:00 Tokyo Standard Time. Location: auditorium, 10, gukhoe-daero 76-gil, yeongdeungpo-gu, seoul South Korea Reported Earnings • Nov 13
Third quarter 2024 earnings released: ₩9.00 loss per share (vs ₩16.00 loss in 3Q 2023) Third quarter 2024 results: ₩9.00 loss per share (improved from ₩16.00 loss in 3Q 2023). Revenue: ₩5.82b (up 51% from 3Q 2023). Net loss: ₩539.1m (loss narrowed 48% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. New Risk • Jul 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). New Risk • May 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩24b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Reported Earnings • May 19
First quarter 2024 earnings released: EPS: ₩3.00 (vs ₩41.66 loss in 1Q 2023) First quarter 2024 results: EPS: ₩3.00 (up from ₩41.66 loss in 1Q 2023). Revenue: ₩9.09b (up 60% from 1Q 2023). Net income: ₩167.1m (up ₩2.84b from 1Q 2023). Profit margin: 1.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. New Risk • Mar 30
New major risk - Revenue and earnings growth Revenue has declined by 8.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 8.9% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). New Risk • Mar 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Buying Opportunity • Jan 08
Now 22% undervalued Over the last 90 days, the stock is up 2.2%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%. Buying Opportunity • Nov 28
Now 20% undervalued Over the last 90 days, the stock is up 2.9%. The fair value is estimated to be ₩10,069, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last year. Earnings per share has grown by 81%. New Risk • Jul 14
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Tillkännagivande • Jun 30
NatureCell Co.,Ltd. announced that it has received KRW 5 billion in funding On June 29, 2023, NatureCell Co.,Ltd. closed the transaction. The scheduled listing of the share is July 14, 2023 and all new stock is locked up for one year from closing date. Tillkännagivande • Jun 14
NatureCell Co.,Ltd. announced that it expects to receive KRW 5 billion in funding NatureCell Co.,Ltd. announced a private placement of 500,000 common shares at a price of KRW 10,000 per share for the gross proceeds of KRW 5,000,000,000 on June 13, 2023. The transaction will include participation from returning investor Jeongchan Ra for 500,000 shares. The shares are restricte to hold period of 1 year. The transaction has been approved by the shareholders of the company. The transaction is expected to close on July 14, 2023. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Apr 14
NatureCell Co.,Ltd. announced that it expects to receive KRW 30 billion in funding NatureCell Co.,Ltd. announced a private placement series 4 bearer type private equity convertible bonds with bearer interest for gross proceeds KRW 30,000,000,000 in a round of funding on April 12, 2022. The transaction will include participation from Green Snake Bio Technology Association No. 1. The bonds will carry a fixed surface interest rate of 1% and maturity rate of 2%. The bonds have a maturity date of May 20, 2025. The bonds are 100% convertible at a fixed conversion price of KRW 17,652 into 1,699,514 common shares from May 20, 2023 to April 20, 2025. The subscription date of the bonds is April 12, 2022. The company expects to close the transaction on May 20, 2022. The transaction was approved by the board of directors of the company. The securities carry a lock up period of one year. Is New 90 Day High Low • Feb 24
New 90-day low: ₩7,840 The company is down 18% from its price of ₩9,510 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 12% over the same period. Tillkännagivande • Feb 10
NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021 NatureCell Co.,Ltd., Annual General Meeting, Mar 30, 2021, at 11:00 Korea Standard Time. Is New 90 Day High Low • Jan 29
New 90-day low: ₩8,900 The company is down 2.0% from its price of ₩9,120 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 16% over the same period. Is New 90 Day High Low • Dec 30
New 90-day high: ₩10,250 The company is up 4.0% from its price of ₩9,850 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is up 1.0% over the same period. Is New 90 Day High Low • Nov 17
New 90-day low: ₩9,110 The company is down 12% from its price of ₩10,350 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is down 8.0% over the same period. Is New 90 Day High Low • Oct 30
New 90-day low: ₩9,120 The company is down 4.0% from its price of ₩9,480 on 31 July 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Food industry, which is down 8.0% over the same period. Tillkännagivande • Sep 01
NatureCell Co.,Ltd. announced that it has received KRW 10 billion in funding On August 26, 2020, NatureCell Co.,Ltd. (KOSDAQ:A007390) closed the transaction. Tillkännagivande • Aug 25
NatureCell Co.,Ltd. announced that it expects to receive KRW 10 billion in funding NatureCell Co.,Ltd. (KOSDAQ:A007390) announced that it will receive KRW 10,000,000,000 in a round of funding on August 24, 2020. The company will issue series 3 non-guaranteed private equity convertible bonds with bearer interest in the transaction. The transaction will include participation from Las Bora Fund. The bonds will carry a fixed surface interest rate of 1% and interest to maturity of 1%. The bonds have a maturity date of August 26, 2023. The bonds are 100% convertible at a fixed conversion price of KRW 10,539 into 948,845 common shares from August 26, 2021 to July 26, 2023. The subscription date of the bonds is August 24, 2020. The transaction was approved by the board of directors of the company. The company expects to close the transaction on August 26, 2020. 
